NKF's subsidiary has obtained the US FDA's registration approval for the transfer of the production site of Etoposide Injection
I'm PortAI, I can summarize articles.
NKF's subsidiary Meitheal Pharmaceuticals, Inc. recently received approval from the U.S. FDA, allowing Jianjin Pharmaceutical Co., Ltd. to produce Etoposide Injection (100 mg/5 mL, 500 mg/25 mL, and 1 g/50 mL). The new product will be launched in the U.S. soon and is expected to have a positive impact on the company's performance
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments